<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_pGYeZrM">The Role of Digital Health Technology Interventions in the Prevention of Type 2 Diabetes Mellitus: A Systematic Review</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Vivien</forename><surname>Nguyen</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> School of Medicine , Western Sydney University , Campbelltown , NSW , Australia.</note>
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">Western Sydney University</orgName>
								<address>
									<settlement>Campbelltown</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paige</forename><surname>Ara</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> School of Medicine , Western Sydney University , Campbelltown , NSW , Australia.</note>
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">Western Sydney University</orgName>
								<address>
									<settlement>Campbelltown</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Simmons</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> School of Medicine , Western Sydney University , Campbelltown , NSW , Australia.</note>
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">Western Sydney University</orgName>
								<address>
									<settlement>Campbelltown</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Translational Health Research Institute , Western Sydney University , NSW , Australia.</note>
								<orgName type="department">Translational Health Research Institute</orgName>
								<orgName type="institution">Western Sydney University</orgName>
								<address>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Uchechukwu</forename><forename type="middle">Levi</forename><surname>Osuagwu</surname></persName>
							<email>l.osuagwu@westernsydney.edu.au</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> School of Medicine , Western Sydney University , Campbelltown , NSW , Australia.</note>
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">Western Sydney University</orgName>
								<address>
									<settlement>Campbelltown</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Translational Health Research Institute , Western Sydney University , NSW , Australia.</note>
								<orgName type="department">Translational Health Research Institute</orgName>
								<orgName type="institution">Western Sydney University</orgName>
								<address>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Bathurst Rural Clinical School (BRCS) , School of Medicine , Western Sydney University , Bathurs , NSW , Australia.</note>
								<orgName type="department" key="dep1">Bathurst Rural Clinical School (BRCS)</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">Western Sydney University</orgName>
								<address>
									<settlement>Bathurs</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<note type="raw_affiliation">Uchechukwu Levi Osuagwu , School of Medicine , Bathurst Rural Clinical School , Western Sydney University , PO Box 9008 , Bathurst , NSW 2795 , Australia.</note>
								<orgName type="department" key="dep1">School of Medicine</orgName>
								<orgName type="department" key="dep2">Bathurst Rural Clinical School</orgName>
								<orgName type="institution" key="instit1">Uchechukwu Levi Osuagwu</orgName>
								<orgName type="institution" key="instit2">Western Sydney University</orgName>
								<address>
									<postBox>PO Box 9008</postBox>
									<postCode>2795</postCode>
									<settlement>Bathurst</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_8s5gzpa">The Role of Digital Health Technology Interventions in the Prevention of Type 2 Diabetes Mellitus: A Systematic Review</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">95F1EF885FFC8B4797303CC86F19C7E4</idno>
					<idno type="DOI">10.1177/11795514241246419</idno>
					<note type="submission">ReCeIveD: July 5, 2023. ACCePTeD: March 26, 2024.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T07:33+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_4z3Wn4m">Digital health</term>
					<term xml:id="_C2Ya8pb">review</term>
					<term xml:id="_vk5BkuD">diabetes</term>
					<term xml:id="_e7dVHRY">hemoglobin A1c</term>
					<term xml:id="_XGwVEVM">health technology</term>
					<term xml:id="_Aswj8qS">health intervention</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_jDskk3B"><p xml:id="_fmpf8JX"><s xml:id="_wWXt8JE">OBjeCTIveS: Diabetes in the 21st century presents one of the greatest burdens of disease on the global population.</s><s xml:id="_apXWQY4">Digitally mediated interventions have become imperative in alleviating this disease epidemic.</s><s xml:id="_fzGQVn7">We aimed to systematically review randomized controlled trials (RCTs) on different health technologies for preventing Type 2 diabetes mellitus, and their efficacy in decreasing diabetes risk-related outcomes in at-risk patients in comparison to standard care.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_sQaN8QW">MeTHODS:</head><p xml:id="_D76QUWJ"><s xml:id="_v8BAvzq">Five electronic databases were searched between October 2021 and December 2022.</s><s xml:id="_B8rjHw5">Studies including digital health technology interventions used for preventing diabetes development by reducing diabetes risk-related outcomes in at-risk adults (⩾18 years) were identified.</s><s xml:id="_kDzxnZu">Data on glycemic levels, incidence of T2DM, weight, and intervention descriptions were extracted, and the risk of bias (ROB) was assessed.</s></p><p xml:id="_JxEysrD"><s xml:id="_xpTbQyZ">ReSulTS: Nine studies met the inclusion criteria and 5 studies (56%) achieved clinically significant outcomes in at least one of the following: decreased weight (22%), glycemic levels (22%), or incidence of T2DM (11%).</s><s xml:id="_mPMa7z4">Two of the 3 (67%) computer-based interventions effectively reduced the HbA1c levels and mean weight of their study population, and 3 of 6 (50%) mobile based interventions (text messages, mobile app, and telehealth) decreased the incidence of T2DM and HbA1c levels.</s><s xml:id="_GbjA5dN">Four studies each had an overall low ROB and one had a high ROB due to attrition.</s></p><p xml:id="_4QpfHDQ"><s xml:id="_msQyGup">COnCluSIOn: Preliminary evidence identified in our review demonstrated that health technologies for diabetes prevention are effective for improving diabetes risk-related outcomes.</s><s xml:id="_aeAHgaq">Future research into digital technology protocol and studies of longer duration and more diverse populations are needed for clinical feasibility.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Xw3QjFx">PlAIn lAnguAge SuMMARy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_scnHBSp">Role of Digital technology in Diabetes prevention</head><p xml:id="_7mGgk6X"><s xml:id="_RFBQemC">In the 21st century, diabetes has become a major health challenge globally.</s><s xml:id="_yrWA9Ur">To address this, we conducted a systematic review, looking at studies that used digital interventions to prevent Type 2 diabetes mellitus (T2DM) and how effective they are compared to standard care.</s><s xml:id="_rUskKCz">In this study, we searched electronic databases from October 2021 to December 2022 and identified 9 studies that met our criteria.</s><s xml:id="_QU4nbGP">These studies focused on adults aged 18 and above who were at risk of developing diabetes.</s><s xml:id="_vq42MHm">We looked at outcomes like glucose concentrations, T2DM incidence, and weight, and assessed the risk of bias in each study.</s><s xml:id="_T9du7zG">The results showed that more than half of the studies showed significant outcomes.</s><s xml:id="_jeNQ6rX">For instance, some interventions led to decreased weight, lower glucose concentrations, or reduced incidence of T2DM.</s><s xml:id="_9NFHkvJ">Computer-based interventions and mobile-based interventions (including text messages, mobile apps, and telehealth) were particularly effective in improving these outcomes.</s><s xml:id="_VYZKagD">In conclusion, our review suggests that digital health technologies can be effective in preventing diabetes and improving related outcomes.</s><s xml:id="_N9uyVqd">However, we note that more research is needed, especially looking at diverse populations and longer study durations, to confirm the clinical feasibility of these digital interventions for diabetes prevention.</s><s xml:id="_krfZ7dX">This is a promising step forward in using technology to tackle the growing diabetes epidemic, offering new ways to support individuals at risk and improve their health outcomes.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_tz4W3kr">Introduction</head><p xml:id="_FEX5Tfr"><s xml:id="_mCZuUqJ">Type 2 Diabetes Mellitus (T2DM) is defined as a metabolic disease involving defective insulin action. <ref type="bibr" target="#b0">1</ref> The resulting hyperglycemia places individuals at high risk for all-cause mortality by health expenditure of around 966 billion USD. <ref type="bibr" target="#b1">2</ref> An estimated 50% of diabetes cases globally remain undetected or undiagnosed <ref type="bibr" target="#b2">3</ref> and over half of diabetes' economic cost lies in its treatment. <ref type="bibr" target="#b1">2</ref></s><s xml:id="_TnZFscf">Diabetes prevention programs (DPPs) are increasingly 2 Clinical Medicine Insights: Endocrinology and Diabetes crucial in mediating this exponential disease epidemic.</s><s xml:id="_mZbzHAs">With healthcare systems' gradual digitalization, the mediation of DPPs through technological platforms can aid in translating and disseminating these preventative interventions into clinical and public health settings.</s></p><p xml:id="_P6szTPh"><s xml:id="_FWgQcrH">Diabetes prevention is traditionally grounded in behavioral change theory, where lifestyle modifications are normalized through educational curriculum, health coaching and peer support in individual and group settings. <ref type="bibr" target="#b3">4</ref></s><s xml:id="_guxjapP">Landmark clinical trials prove that intensive lifestyle interventions targeting physical activity and healthy diets are effective in reducing the progression from prediabetes to diabetes by 58% in comparison to pharmacological interventions. <ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref></s><s xml:id="_cUzskaG">6]<ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref> They yield long-term results at follow-up with a T2DM reduction of up to 43% that persists for decades for particular populations, <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b5">6</ref> but with the growing global incidence of diabetes, this evidence requires translation into a multifaceted systems approach. <ref type="bibr" target="#b8">9</ref></s><s xml:id="_2HgAVUH">In a public health setting, literature indicates the need to develop local health economies that facilitate communication and accessibility between the different levels of health care. <ref type="bibr" target="#b8">9</ref></s><s xml:id="_TDwJbd7">At the patient level, barriers to accessibility and adherence need to be overcome. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b9">10</ref></s><s xml:id="_ZgbdXq5">At the clinical practice level, the increasing prevalence of diabetes-related complications <ref type="bibr" target="#b8">9</ref> requires a shift of patient management from episodic primary physician checks to a chronic care model. <ref type="bibr" target="#b10">11</ref></s><s xml:id="_UhkAdDY">At an administrative level, the economic burden on public health systems can be ameliorated by socio-structural change via health policies, health education <ref type="bibr" target="#b11">12</ref> and the development of supportive community environments. <ref type="bibr" target="#b12">13</ref></s><s xml:id="_dDWvfgT">igital health technology refers to the use of digital and information technologies, such as mobile devices, wearables, health information systems, software applications, and telehealth services, to improve the delivery and management of healthcare. <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15</ref></s><s xml:id="_yr7gzzN">It covers a wide range of tools and solutions crafted to improve the efficiency, accessibility, and quality of healthcare services while empowering individuals to actively engage in their health management.</s><s xml:id="_nNKNBWu">The origins of digital health technology can be traced back to the integration of computers into healthcare settings during the mid-20th century.</s><s xml:id="_wQvqpxq">Initially used for administrative tasks, these technologies gradually expanded to encompass clinical and patient care. <ref type="bibr" target="#b15">16</ref></s><s xml:id="_JbeDPQy">he rapid evolution of digital health technology was further fueled by the advent of the internet and the widespread use of personal computing devices.</s><s xml:id="_kNMTbNe">Over the past few decades, there has been a notable surge in the development and acceptance of digital health solutions.</s><s xml:id="_Hzvrf8a">The widespread adoption of smartphones, wearable devices, and the availability of high-speed internet have been pivotal factors contributing to this growth. <ref type="bibr" target="#b16">17</ref></s><s xml:id="_Nwy8AmR">igital health technologies now encompass a diverse array of applications, including electronic health records (EHRs), telemedicine, mobile health apps, remote patient monitoring, health informatics, and the utilization of artificial intelligence for healthcare analytics. <ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19</ref></s><s xml:id="_cdqzWWT">rman 20 identified the key shared features accounting for the success of major DDP trials.</s><s xml:id="_NUmJc7q">These include individualization of patient interventions, flexibility between group and individual settings, a mixture of physical and behavioral activities and an "extensive network of training, feedback and clinical support." <ref type="bibr" target="#b0">1</ref> Evidence indicates that health technologies fulfill all these criteria by extending diabetes prevention from clinical settings to creating an individual's daily health-protective environment. <ref type="bibr" target="#b9">10</ref></s><s xml:id="_AhqYWSs">Health technologies act as intermediary platforms that transfer information between patient and provider whilst normalizing behavioral interventions and lifestyle modifications in the patients' surroundings and communities.</s></p><p xml:id="_TyEW5rT"><s xml:id="_3RE9w9x">Regarding computer-based interventions, there is little evidence of its impact on diabetes prevention as software focuses on known diabetes and population management between various health providers, remote patient monitoring and diabetes self-management. <ref type="bibr" target="#b20">21</ref></s><s xml:id="_B2gz2sj">A Cochrane meta-analysis comparing 16 computer-mediated diabetes education programs demonstrated a small decrease in HbA1c in patients diagnosed with T2DM and has potential in translation to preventative interventions. <ref type="bibr" target="#b21">22</ref></s><s xml:id="_JDevjnh">here is also a paucity of data on the efficacy of digital health technology in diabetes prevention.</s><s xml:id="_x3MAFEq">Past studies that showed evidence of positive correlations between digitally translated DPPs and improved diabetes risk-related outcomes have been limited by their short duration (5-24 months) and the lack of long-term follow-up.</s><s xml:id="_aVpj9bT">These affect the predictive validity of results by not accounting for fluctuating weight and glycemic levels.</s><s xml:id="_AZUq9tD">The heterogeneity of study location and participant demographic and high variability in program procedure affects the feasibility of public health implementation and scalability as study outcomes may not be generalizable to other national or global contexts.</s><s xml:id="_5Wbp7Du">Due to these research gaps, this paper aims to systematically review and compare current evidence about digitalized DPPs' efficacy in reducing the incidence of diabetes and identify any shared features that may assist in optimizing current interventions and improving health outcomes for at-risk individuals.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Kce2FJk">Methods</head><p xml:id="_M6ZfXxQ"><s xml:id="_kpjApnH">This systematic review was conducted using guidelines from the Cochrane Handbook for Systematic Reviews of Interventions <ref type="bibr" target="#b22">23</ref> and the protocol was registered with the International Prospective Register of Systematic Reviews PROSPERO (#: CRD42022344100).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XJ7qWRt">Search strategy</head><p xml:id="_gS47z4Y"><s xml:id="_rczjyyC">A systematic literature search was conducted using 5 electronic databases (PubMed, EBSCO, Ovid Medline, EMBASE and Cochrane Library) in October 2022 with a search strategy structured using the PICO tool <ref type="bibr" target="#b23">24</ref> consisting of related keywords and medical subject headings (MeSH) as seen below:</s></p><p xml:id="_eSDJH9Z"><s xml:id="_XVTJqxn">• • Population: T2DM, prediabet* • • Intervention: Technology health, digital technology, biomedical technology • • Comparison: standard treatment, control • • Outcomes: decrease* risk, weight loss, decreas* BMI, decreas* blood glucose, decreas* hyperglycemia, improv* glycemic control, decreas* waist circumference Boolean search terms "OR" and "AND" enforced a distinction between specified and generalized terms.</s><s xml:id="_vRxsVsa">Filters limiting peerreviewed journal articles to randomized controlled trials (RCTs) and study recency to the last 10 years were applied.</s><s xml:id="_k6R8H4a">The final search strategy was as follows: (((MM T2DM OR prediabet*[MeSH Major Topic]) AND (standard treatment OR control)) AND (MM Technology, health OR digital technology OR biomedical technology)) AND (decreas* risk OR weight loss OR decreas* BMI OR decreas* blood glucose OR decreas* hyperglycemia OR improv* glycemic control OR decreas* waist circumference).</s><s xml:id="_fTgZqFa">The same search strategy was replicated across the various databases.</s><s xml:id="_9JBk2wn">Eligibility criteria Titles and abstracts of studies were screened by 2 independent reviewers (VN, PA) for eligibility.</s><s xml:id="_BCPq7Gz">Results were compared to finalize selection and any disagreements were resolved through discussion.</s><s xml:id="_6Hwb35v">Studies were eligible for inclusion if they: (i) assessed adult (&gt;18 years) populations who were at risk of developing diabetes; (ii) involved technology-based interventions which could be fully digitally-mediated or delivered in a mixed digital and face-to-face format; (iii) involved interventions explicitly aimed at reducing the risk of diabetes development; (iv) had outcome features related to body weight, glycemic levels or T2DM incidence (decreased BMI, decreased waist circumference, weight loss percentage, decreased fasting blood glucose or HbA1c); (v) in the RCT study format; and (vi) are available in English with full text.</s><s xml:id="_9r8J8ff">Exclusion criteria included: (i) studies involving populations with diabetes diagnoses; (ii) interventions with no digital technology component; and (iii) interventions aimed at managing existing diabetes rather than preventing diabetes incidence.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_pMUqjWU">Data extraction</head><p xml:id="_sRnpaYy"><s xml:id="_crEySP8">Due to the small scale of the systematic review (2 reviewers and less than 20 studies), data was stored using standard data extraction templates on Google Forms based on Cochrane guidelines. <ref type="bibr" target="#b22">23</ref></s><s xml:id="_7JNqsXb">Data was extracted from all studies by 1 reviewer (VN) then a second reviewer (PG) independently repeated extraction on a random 20% of selected studies to confirm accuracy.</s><s xml:id="_DWwfWmP">Disagreements were resolved with discussion.</s><s xml:id="_N9fv93d">Data about primary outcomes related to reducing diabetes risk were sought for extraction to compare intervention efficacy.</s></p><p xml:id="_xSBvn8y"><s xml:id="_cs4gcyX">Studies were grouped by these primary outcomes (decreased BMI, weight, glycemic levels, and T2DM incidence) and the mean and standard deviation of baseline and end-of-study results were tabulated with P-values and confidence intervals, where available, to compare statistical significance.</s><s xml:id="_5jh4KUW">Study variables extracted include the following intervention characteristics: author, year of publication, population sample size, study design, country of study, the study's definition of "at-risk" and intervention characteristics, primary outcome unit of measurement and study duration.</s><s xml:id="_WuShCjX">Narrative synthesis was chosen to summarize these intervention characteristics and outcomes due to clinical heterogeneity (population baseline characteristics and intervention methods) and methodological heterogeneity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_e29ey2s">Assessing bias</head><p xml:id="_HfKKUhs"><s xml:id="_F6eb7wQ">The quality of selected studies was assessed for risk of bias (RoB) using the Cochrane Collaboration Tool 25 by 1 reviewer (VN).</s><s xml:id="_nGtJvCz">A random 20% of studies were screened by a second reviewer (PG) to confirm reliability.</s><s xml:id="_ZBAxGpp">Disagreements were resolved with discussion.</s><s xml:id="_GkYfm8C">Studies were rated either "low risk," "some concerns" or "high risk" over 5 different domains.</s><s xml:id="_W5JgyYy">They were deemed "low risk" if they scored "low risk" on all domains or if the domains of "some concern" were highly unlikely to affect study results and deemed "high risk" if they scored "high risk" in at least 1 domain.</s><s xml:id="_Euu6Wpt">Results were presented in Robvis <ref type="bibr" target="#b25">26</ref> traffic light and weighted bar plots.</s></p><p xml:id="_MY92vsZ"><s xml:id="_W45pFN4">Quality of evidence was assessed using the GRADE scale 27 where reviewers' confidence in the similarity of the true effect and the estimated effect were graded by 4 levels of certainty-"high," "moderate," "low," and "very low."</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UP2u2NJ">Results</head><p xml:id="_2jtW9jY"><s xml:id="_xzsjNKq">Reporting of the study findings followed the Prisma protocol as shown in the checklist (see Supplemental Table <ref type="table" target="#tab_2">1</ref>).</s><s xml:id="_u6AUy8c">The PRISMA flow diagram <ref type="bibr" target="#b27">28</ref> shown in Figure <ref type="figure">1</ref> details the process of study selection and reasons for exclusion.</s><s xml:id="_dKcwR6D">The initial literature search identified 226 articles and after duplicates were removed 151 publications were screened by title and abstract.</s><s xml:id="_8B7vgsj">Forty studies were sought for retrieval and 1 study was not available on public databases.</s><s xml:id="_uW9WqeM">Thirty-nine studies from the following databases, PubMed (8), Ebsco (3) Ovid Medline ( <ref type="formula">14</ref>), Cochrane (6), and other sources (8) underwent double screening and were assessed for eligibility after which 9 studies were included in this systematic review.</s></p><p xml:id="_WbdSpD6"><s xml:id="_SNNexh9">The basic characteristics of the reviewed studies are summarized in Table <ref type="table" target="#tab_2">1</ref>.</s><s xml:id="_DuAKuE5">Four of the studies that were included in the full-text review were from PubMed, 3 from Cochrane, and 2 from Medline libraries.</s><s xml:id="_qxWpSDp">Many of the studies (n = 44.4%)</s><s xml:id="_Egpvsrw">were conducted in America <ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref> with a single study site each in New Zealand, <ref type="bibr" target="#b33">34</ref> India, <ref type="bibr" target="#b34">35</ref> Hong Kong, <ref type="bibr" target="#b35">36</ref> Bangladesh, <ref type="bibr" target="#b36">37</ref> and 1 jointly conducted in the UK and India. <ref type="bibr" target="#b30">31</ref></s><s xml:id="_fDebwmw">Eight out of 9 studies were parallel 2-arm RCTs <ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref> while 1 study was a 3-arm cluster RCT. <ref type="bibr" target="#b36">37</ref></s><s xml:id="_8y3f4uX">Six studies recruited participants from primary healthcare settings <ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref> , 3 studies recruited from the workplace, <ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref> and 1 from the community. <ref type="bibr" target="#b36">37</ref></s><s xml:id="_QGmWtHa">ight (89%) out of 9 studies' populations were of mixed gender <ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b36">37</ref> with 1 study population being exclusively male. <ref type="bibr" target="#b34">35</ref> Th</s><s xml:id="_TGyaFGz"> 4 American studies defined an individual at risk of diabetes or in the prediabetes stage with HbA1c scores of 5.7% to 6.4% or 39 to 46 mmol/mol.</s><s xml:id="_Vy6ajjV"><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b32">33</ref> Other studies recruited participants in the upper prediabetes range (HbA1c &gt; 5.9%) <ref type="bibr" target="#b31">32</ref> or defined at-risk populations by BMIs greater than 23 kg/m 2 , positive family histories of type 2 diabetes mellitus (T2DM), oral glucose tolerance test scores (14-200 mg/dL) or fasting plasma glucose scores (100-125 mg/dL).</s><s xml:id="_g3Qd7Pf"><ref type="bibr" target="#b34">35</ref> Intervention methods varied across studies where differing combinations of health coaching, educational resources, peer support groups and goal tracking were mediated through various digital platforms. <ref type="bibr" target="#b28">[29]</ref></s><s xml:id="_KdtfET5">]<ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref> A single intervention <ref type="bibr" target="#b30">31</ref> used individually tailored websites and interactive emails while 7 interventions <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref> used mobile devices via text or voice messages, <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref> telephone-mediated coaching <ref type="bibr" target="#b28">29</ref> or mobile applications.</s><s xml:id="_6QCHQ5V"><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b33">34</ref> Digital technology was supplementary to in-person or online coaching by a health coach in 5 studies <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b36">37</ref> , four studies were automated and algorithm-driven.</s><s xml:id="_K9MhdnQ"><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref> Table <ref type="table" target="#tab_4">2</ref> summarizes the primary outcomes and results of the included studies.</s><s xml:id="_EtgMF43">Three studies <ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b33">34</ref> determined intervention Records identified from: Databases (n=226) Registers (n=5) Records removed before screening: Duplicate records removed (n=75) Records marked as ineligible by automation tools (n=0) Records removed for other reasons (n=0) Records screened (n=151) Records excluded(n=111) Reports sought for retrieval (n=40) Reports not retrieved (n=1) Reports assessed for eligibility (n=39) Reports excluded: Wrong study design (n=13) Wrong population (n=2) Wrong intervention (n=4) Wrong outcomes (n=5) Incomplete study -protocol only (n=6) Studies included in review (n=9) Reports of included studies(n=0) Identification of studies via databases and registers Identification Screening Included Figure 1.</s><s xml:id="_JMd9gJR">Flowchart of study selection.</s><s xml:id="_N7Nn6uT">Four studies <ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref> examined an outcome of diabetes incidence in relation to DPP interventions mediated over mobile phone messaging with 3 studies <ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref> yielding clinically significant results.</s><s xml:id="_teCQcg7">Ramachandran et al <ref type="bibr" target="#b37">38</ref> and Wong et al's <ref type="bibr" target="#b35">36</ref> studies examining behavioral change theory-oriented text messages both affected the lower cumulative incidence of T2DM in</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NEzmxsb">Risk of bias</head><p xml:id="_eXRPtvH"><s xml:id="_nqJeFKR">Using Cochrane Collaboration Tool's RoB 2, <ref type="bibr" target="#b24">25</ref> Figure <ref type="figure" target="#fig_0">2</ref> details the result of assessment by domains for the selected studies.</s><s xml:id="_K7HBmkT">Four studies were identified with an overall low ROB, <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b36">37</ref> another with a high ROB due to attrition (incomplete follow-up and patient retention) <ref type="bibr" target="#b35">36</ref> and for 4 other studies, there were some concerns of attrition bias (patient non-compliance or retention) to a lesser degree. <ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref></s><s xml:id="_DWRkQbQ">32]<ref type="bibr" target="#b33">34</ref> There was no selection bias in the reviewed studies due to the adequate randomization and allocation concealment in the studies.</s><s xml:id="_fWMDxJF">Regarding performance bias, by nature of the interventions, the majority of patients and caregivers could not be blinded but this did not affect study outcomes.</s><s xml:id="_pE8yDzC">Detection bias was present in 2 studies whose outcomes were not statistically significant <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b35">36</ref> and no reporting bias was identified as all measured outcomes were reported in the final analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4bzDx6J">Discussion</head><p xml:id="_wm6Dxpf"><s xml:id="_bMNKGuv">This review study identified 5 studies <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref> that showed clinically significant reductions of various diabetes risk related outcomes especially glycemic levels, weight, BMI and reduced incidence of T2DM, possibly strengthening available literature on the efficacy of 2 main digital modalities (computer and mobile devices) in diabetes prevention.</s><s xml:id="_K2ZuQ35">Despite the statistical significance of these RCTs, the studies were significantly heterogeneous in their outcomes due to the large variation in the intervention methods.</s><s xml:id="_JqQTufP">The study findings suggest that the efficacy of individual DPPs may be due to the synergistic effect of various modes of delivery (technological and in-person) rather than the superiority of one modality over the others.</s><s xml:id="_bf2vgWe">However, due to the small number of studies about each digital modality, the impact of these variations in the intervention could not be properly assessed.</s><s xml:id="_ja9dumy">In this study, there were 2 RCTs 31,33 involving computerbased DPPs that yielded statistically significant results, proving the capacity of computers to fully automate DPPs or to act in a supplementary role -providing resources alongside in-person curriculums.</s><s xml:id="_mTEAHMG">For one study, <ref type="bibr" target="#b30">31</ref> after 6 months, the use of individualized websites and interactive emails improved the glycemic level, body weight and 8-year diabetes risk of people with prediabetes.</s><s xml:id="_EUnKZb4">The use of computer-mediated peer support groups, tracking and behavioral change curriculums yielded significant weight loss at 12 months, <ref type="bibr" target="#b32">33</ref> whereas mobile-mediated interventions led to positive outcomes such as greater weight loss over time and reduction in the risk of developing diabetes at 12 months. <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref></s><s xml:id="_uHg793s">A text-messaging intervention where delivered content was individualised <ref type="bibr" target="#b38">39</ref> and one where messages were standardized to collective participant preferences, <ref type="bibr" target="#b35">36</ref> both decreased the cumulative incidence of T2DM.</s><s xml:id="_EZKvMyV">In agreement with previous evidence, <ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40</ref> supporting in-person DPP sessions with a mobile app for tracking progress and mediating educational resources achieved clinically significant weight loss, <ref type="bibr" target="#b29">30</ref> thus affirming the strength of mobile-mediated interventions in increasing patient adherence through positive reinforcement. <ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40</ref></s><s xml:id="_kMCudDa">This has also been linked to high retention rates in clinical trials. <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref></s><s xml:id="_bpzPD45">]<ref type="bibr" target="#b36">[37]</ref> On the other hand, mobile-mediated DPPs are effective in consistently reinforcing patient education, <ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b40">41</ref> self-monitoring and social support <ref type="bibr" target="#b38">39</ref> which prevents non-adherence.</s><s xml:id="_pmeXeGX">The high global levels of smartphone ownership <ref type="bibr" target="#b39">40</ref> further decrease economic expenditure and accommodate a widespread dissemination of intervention programs.</s><s xml:id="_famWEnJ">Four text message-based programs focused on stage-based behavioral change were shown to significantly reduce the progression of prediabetes to diabetes with preventative outcomes of weight loss and diet logging. <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b41">42</ref></s><s xml:id="_tXtr4Av">In examining a broad digitalization of DPPs, a 2017 meta-analysis correlates smartphone apps mediating health professional personal contact with increased weight loss, in comparison to complete automated contact. <ref type="bibr" target="#b42">43</ref></s><s xml:id="_wcHSYaD">vidently, by replacing in-person group exercise sessions with phone-app delivered home regimens, Fukuoka et al's <ref type="bibr" target="#b29">30</ref> intervention yielded no change in glucose levels, supporting how retaining partial human factors in delivery is still imperative in patient adherence and response.</s></p><p xml:id="_62QyGmB"><s xml:id="_dyveMxC">Regarding the effect of computer-based therapies in decreasing HbA1c in at-risk patients, the evidence is judged to be moderate in quality.</s><s xml:id="_mHAMBfY">The studies have a generally low risk of bias besides some concerns of attrition for participant retention. <ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b32">33</ref></s><s xml:id="_ZNp9qVC">There is no great imprecision, indirectness, or publication bias but the heterogeneity of the intervention method and the data of statistical significance only being sourced from 3 studies, lowers confidence in the review's results.</s><s xml:id="_ZwgYWrC">For mobilebased therapies and their impact on reducing the incidence of T2DM, the evidence is judged to be of low quality.</s><s xml:id="_HxeCRvA">There is moderate to high risk in 2 out of 3 studies of statistical significance and the sample size in those studies was small (61 and 104 participants). <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b35">36</ref></s><s xml:id="_ucNbsWY">The RCTs have no obvious imprecision, indirectness, or publication bias but the heterogeneity of intervention and study protocol were variable.</s></p><p xml:id="_8pdbYtT"><s xml:id="_GQkksa9">Digital health technology interventions play a pivotal role in augmenting existing strategies for the prevention of type 2 diabetes mellitus (T2DM).</s><s xml:id="_YNxnGrZ">These interventions leverage innovative technological solutions to enhance outreach, education, monitoring, and management of individuals at risk for T2DM.</s><s xml:id="_4eJktyr">By incorporating mobile applications, wearable devices, and online platforms, digital health technologies provide personalized and real-time interventions, promoting lifestyle modifications and behavior change.</s><s xml:id="_2CtZZSm">These tools facilitate continuous glucose monitoring, physical activity tracking, and dietary management, empowering individuals to take an active role in their health.</s><s xml:id="_jHfE6nw">Moreover, digital interventions enable healthcare providers to remotely monitor patients, offer timely if not real-time feedback, and tailor interventions based on individual progress.</s><s xml:id="_tWgMWQN">The integration of data analytics and machine learning further refines predictive models, identifying high-risk populations and customizing intervention strategies.</s><s xml:id="_yxZSeBK">In essence, digital health technology interventions not only complement but also transform conventional approaches to T2DM prevention, fostering a more dynamic, individualized, and proactive healthcare paradigm.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XFVsgvB">Implications for practice</head><p xml:id="_5kDHspZ"><s xml:id="_k8VhJx2">This study provided evidence for the generalized efficacy of health technologies in preventing diabetes by reducing riskrelated outcomes as 5 studies within this review demonstrated statistically significant reductions in HbA1c and diabetes incidence.</s><s xml:id="_HJnCngU">Further research is needed to translate this data into clinical settings.</s><s xml:id="_gfxmjfy">The feasibility of digitally mediated DPPs is supported by the gradual modernization of the healthcare system and public accessibility to technology but this can be better understood with more pragmatic trials involving diverse populations or interventions that are culturally adapted (which showed a positive outcome in one study. <ref type="bibr" target="#b28">29</ref></s><s xml:id="_kcg39tG">We also provided evidence of appropriateness, as diabetes prevention involves self-management and literature which identifies mobiledevices efficacy in increasing patient engagement <ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40</ref> and the high retention rates of studies within this review <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref> support this.</s><s xml:id="_ZcWkMWx">Evidence of meaningfulness was unavailable as patient-rated outcomes were not examined in this review and effectiveness is difficult to determine with the moderate to low quality evidence of the chosen studies.</s></p><p xml:id="_7fvyFSu"><s xml:id="_xrmfZQG">Establishing a sustainable infrastructure for digital diabetes prevention programs is imperative for its long-term success.</s><s xml:id="_tpnUYSn">This infrastructure should prioritize interoperability with existing health information systems, ensuring seamless data exchange and continuity of care.</s><s xml:id="_HKN5S3v">Robust cybersecurity measures, including secure data storage and transmission, are essential to protect patient information and comply with healthcare data protection regulations.</s><s xml:id="_7JkFeSG">The use of scalable, cloud-based architecture enables flexibility and accommodates a growing user base, while user-friendly interfaces cater to a diverse range of users.</s><s xml:id="_E3asQg9">Integration with wearable and IoT devices allows for real-time data collection, and analytics tools provide insights for continuous program improvement.</s><s xml:id="_uFWuYEY">Training modules and support mechanisms ensure both healthcare providers and end-users can effectively utilize the program.</s><s xml:id="_3Kj2UtM">Regulatory compliance frameworks, reliable telecommunication infrastructure, and continuous monitoring and maintenance further contribute to the infrastructure's resilience.</s><s xml:id="_FgFq52E">By addressing these components comprehensively, digital diabetes prevention programs can seamlessly integrate into healthcare systems, promoting sustained engagement and positive health outcomes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bDmuwx9">Limitations and future research</head><p xml:id="_ZVxSQx3"><s xml:id="_PRu4nru">The following limitations should be considered when interpreting this data.</s><s xml:id="_jxMVJcA">First, there was a small number of studies that met the eligibility criteria in this systematic review and the heterogeneity of study design (population, intervention mode of delivery, method, duration) collectively led to difficulty in comparison and inability to perform a meta-analysis to assess the strength of data.</s><s xml:id="_n8mxFcp">Although we have restricted the studies to increase the robustness of our study, future studies might include other non-RCTs for a better understanding of the impact of DPPs.</s><s xml:id="_M8bzQET">Second, the study populations in the included studies lacked diversity which could affect the scalability and accessibility of these interventions.</s><s xml:id="_eecSzaF">The fact that some studies were single-gendered, others recruited from specific workplaces or ethnic groups without cultural adaptation of the DPP program, may have affected the participant engagement.</s><s xml:id="_9UtffrK">Third, the study durations were short ranging from 5 to 36 months with the longest follow-up at 24 months and both these factors limit the external validity of DPP interventions which target a chronic and global health issue.</s><s xml:id="_r6AeG7N">Also, the reviewed studies were all written in English including the Hong Kong Study.</s><s xml:id="_yNG9PNX">This could potentially exclude crucial findings from studies not written in English.</s><s xml:id="_A26gJEg">Articles not written in English from non-English speaking jurisdictions should also be reviewed in future studies.</s></p><p xml:id="_zHBJwV5"><s xml:id="_bB7FuYF">In this study, we identified a research gap with studies that examined specific aspects of health technologies for increased patient engagement.</s><s xml:id="_M2UkqJV">Two studies imply the importance of partial human factors in interventions, attributing high retention rates to healthcare staff delivering the intervention <ref type="bibr" target="#b26">27</ref> and the participatory in-person activities. <ref type="bibr" target="#b36">37</ref></s><s xml:id="_wXxjx6D">Therefore, studying the interactive nature of digital and in-person modalities may optimize intervention protocol.</s><s xml:id="_arE6uUA">Understanding the difference between personalized or standardized interventions and full automation or partial digital mediation is important and can be further explored in future studies.</s></p><p xml:id="_HgeRJJk"><s xml:id="_kw6YtSZ">An examination of diverse digital health approaches across different populations, healthcare systems, and cultural contexts is needed to develop targeted and culturally sensitive digital intervention solutions.</s><s xml:id="_Y4Fh5hj">Also, research should focus on identifying determinants of successful implementation, such as user engagement, usability, and adherence, to optimize intervention designs for maximum impact.</s><s xml:id="_39T2ZX3">Thirdly, continuous evaluation of digital interventions over the long term is crucial to assess their effectiveness and sustainability, informing potential updates or modifications.</s><s xml:id="_CPTKxjw">Fourthly, exploring the integration of digital health technologies into existing healthcare systems, considering interoperability, data security, and impact on workflows, is essential for successful implementation on a broader scale.</s><s xml:id="_ZwKR532">Lastly, investigating the cost-effectiveness and scalability of these interventions will be vital for their widespread adoption and integration into routine healthcare practices.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_6uFpWZU">Conclusion</head><p xml:id="_qFTpet6"><s xml:id="_cZfU6qX">In conclusion, this review supports the current literature's generalized perspective on the efficacy of health technology in diabetes prevention and presents some evidence of positive correlations between digitally translated DPPs and improved diabetes risk-related outcomes.</s><s xml:id="_xktNw5Q">Yet, the heterogeneity in intervention protocol and study procedure and the lack of diverse populations or long-term data and follow-up undermine the possibilities of clinical effectiveness and the feasibility of public health implementation and scalability due to the risk of economic burden and the chance of patient non-adherence.</s><s xml:id="_EnzZjSs">Future research should include studies of larger diverse populations with longer duration and followup data and specific aspects of health technologies that increase patient engagement and the possibility of clinically significant outcomes.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2 .</head><label>2</label><figDesc><div><p xml:id="_6kkkQ6M"><s xml:id="_GHfCC6M">Figure 2. Risk of bias assessment for the various domains.</s></p></div></figDesc><graphic coords="8,87.64,76.54,420.00,379.44" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_jQDTKGJ"><s xml:id="_DBBEfmz">Characteristics of the selected articles.</s></p></div></figDesc><table><row><cell>iNTERVENTiON</cell><cell></cell><cell></cell><cell>BetaMe: Mobile-device</cell><cell>and web-based program</cell><cell>with individual health</cell><cell>coaching, educational</cell><cell>resources, peer support</cell><cell>forums, online goal</cell><cell>tracking</cell><cell></cell><cell></cell><cell></cell><cell>Alive-PD: individualized</cell><cell cols="2">websites, interactive</cell><cell cols="2">emails, mobile app,</cell><cell cols="2">automated phone calls,</cell><cell cols="2">virtual teams</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Mobile-based Diabetes</cell><cell cols="2">Prevention Program</cell><cell cols="2">(mDPP): in-person lifestyle</cell><cell cols="2">intervention sessions,</cell><cell cols="2">interactive mobile app,</cell><cell cols="2">pedometer</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Text-message</cell><cell>enhancement of DPP</cell><cell>classes</cell><cell>Optional individual</cell><cell>motivational interviewing</cell><cell>with a health coach via</cell><cell>telephone</cell><cell>Text messages based on</cell><cell>behavioral change tailored</cell><cell>to participants</cell><cell>Personalized education</cell><cell>and motivation about a</cell><cell>healthy lifestyle at baseline</cell><cell>by a health coach</cell><cell>Text messages:</cell><cell>educational, motivational,</cell><cell>and supportive content on</cell><cell>diet, physical activity,</cell><cell>lifestyle, and smoking</cell><cell>(Continued)</cell></row><row><cell>POPULATiON</cell><cell>DEFiNiTiONS OF</cell><cell>AT-RiSk</cell><cell>hbA1c 41-70 mmol/</cell><cell>mol (5.9%-8.6%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">BMi ⩾ 27 kg/m 2 ,</cell><cell cols="2">fasting glucose 5.55</cell><cell cols="2">to 6.94 mmol/L or</cell><cell cols="2">hbA1c 39 to</cell><cell cols="2">46 mmol/mol,</cell><cell cols="2">(5.7%-6.4%)</cell><cell></cell><cell></cell><cell></cell><cell cols="2">BMi ⩾ 25, age ⩾ 35,</cell><cell cols="2">diabetes test</cell><cell cols="2">scores ⩾ 5, fasting</cell><cell cols="2">plasma glucose of</cell><cell cols="2">100 to 125 mg/dL,</cell><cell cols="2">hbA1c 57% to 7.0%,</cell><cell cols="2">OgTT 12 to 200 mg/</cell><cell cols="2">dL</cell><cell></cell><cell>Adults with</cell><cell>prediabetes</cell><cell>(glycated hemoglobin</cell><cell>(hbA1c) from 5.7%</cell><cell>through 6.4% and</cell><cell>BMi between 25 and</cell><cell>50 kg/m 2</cell><cell>Positive family</cell><cell>history of T2DM or a</cell><cell>BMi of 23 kg/m 2</cell><cell>Prediabetes (upper</cell><cell>range): hbA1c 6.0%</cell><cell>to 6.4% (42-47 mmol/</cell><cell>mol)</cell></row><row><cell>COUNTRY</cell><cell></cell><cell></cell><cell>New</cell><cell>zealand</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>America</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>America</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>America</cell><cell>india</cell><cell>Uk and</cell><cell>india</cell></row><row><cell>STUDY</cell><cell>DESigN</cell><cell></cell><cell>Parallel-group</cell><cell>two-arm</cell><cell>single-blinded</cell><cell>RCT</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>RCT</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>RCT</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>RCT</cell><cell>prospective</cell><cell>parallel-group</cell><cell>RCT</cell><cell>RCT</cell></row><row><cell>RACE/EThNiCiTY</cell><cell></cell><cell></cell><cell>intervention</cell><cell>Maori 32</cell><cell>Pacific 6</cell><cell>All others 177</cell><cell>Control</cell><cell>Maori 33</cell><cell>Pacific 10</cell><cell>All others 171</cell><cell></cell><cell></cell><cell>intervention</cell><cell cols="2">White 109</cell><cell cols="2">hispanic 7</cell><cell cols="2">Asian 41</cell><cell cols="2">Other 6</cell><cell cols="2">Control</cell><cell>White 120</cell><cell>hispanic 14</cell><cell>Asian 29</cell><cell>Other 13</cell><cell>intervention</cell><cell cols="2">Asian 33.4</cell><cell cols="2">Black/African American 0.0</cell><cell cols="2">hispanic/Latino 13.3</cell><cell cols="2">White (non-hispanic) 43.3</cell><cell cols="2">Mixed race10.0</cell><cell cols="2">Control</cell><cell cols="2">Asian 12.9</cell><cell>Black/African American 9.7</cell><cell>hispanic/Latino 9.7</cell><cell>White(non-hispanic) 61.3</cell><cell>Mixed race 6.4 s</cell><cell>intervention</cell><cell>English speaking 27</cell><cell>Spanish speaking 51</cell><cell>Control</cell><cell>English speaking 45</cell><cell>Spanish speaking 34</cell><cell>All participants were indian</cell><cell>men</cell><cell>intervention</cell><cell>indians 584</cell><cell>Uk residents 447</cell><cell>Control</cell><cell>indians 587</cell><cell>Uk residents 444</cell></row><row><cell>SEx</cell><cell></cell><cell></cell><cell>intervention</cell><cell>Male 108</cell><cell>Female 107</cell><cell>Control</cell><cell>Male 103</cell><cell>Female 111</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>intervention</cell><cell cols="2">Male 48</cell><cell cols="2">Female 52</cell><cell cols="2">Control</cell><cell cols="2">Male 46</cell><cell cols="2">Female 54</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>intervention</cell><cell cols="2">Male 23.3</cell><cell cols="2">Female 76.7</cell><cell cols="2">Control</cell><cell cols="2">Male 22.6</cell><cell cols="2">Female 77.4</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>intervention</cell><cell>Male 23</cell><cell>Female 55</cell><cell>Control</cell><cell>Male 15</cell><cell>Female 64</cell><cell>Men only</cell><cell>study</cell><cell>intervention</cell><cell>271</cell><cell>Control</cell><cell>266</cell><cell>intervention</cell><cell>Male 658</cell><cell>Female 373</cell><cell>Control</cell><cell>Male 661</cell><cell>Female 370</cell></row><row><cell>AgE</cell><cell></cell><cell></cell><cell>intervention</cell><cell>25-44 y 10</cell><cell>45-54 y 33</cell><cell>55-64 y 76</cell><cell>65-75 y 96</cell><cell>Control</cell><cell>25-44 y 14</cell><cell>45-54 y 40</cell><cell>55-64 y 71</cell><cell>65-75 y 89</cell><cell>intervention</cell><cell cols="2">Mean age (y)</cell><cell cols="2">52.0</cell><cell cols="2">Control</cell><cell cols="2">Mean age (y)</cell><cell cols="2">54.0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>intervention</cell><cell cols="2">Mean age (y)</cell><cell cols="2">57.1</cell><cell cols="2">Control</cell><cell cols="2">Mean age (y)</cell><cell cols="2">53.4</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>intervention</cell><cell>Mean age (y)</cell><cell>47.7</cell><cell>Control</cell><cell>Mean age (y)</cell><cell>45.2</cell><cell>intervention</cell><cell>Mean age (y)</cell><cell>45.9</cell><cell>Control</cell><cell>Mean age (y)</cell><cell>46.1</cell><cell>intervention</cell><cell>Mean age (y)</cell><cell>52.1</cell><cell>Control</cell><cell>Mean age (y)</cell><cell>52.0</cell></row><row><cell>SAMPLE SizE</cell><cell></cell><cell></cell><cell>Total-429</cell><cell>intervention-215</cell><cell>Control-214</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Total-339</cell><cell cols="2">intervention-153</cell><cell cols="2">Control-176</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Total-61</cell><cell cols="2">intervention-30</cell><cell cols="2">Control-31</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Total-163</cell><cell>intervention-82</cell><cell>Control-81</cell><cell>Total-537</cell><cell>intervention-271</cell><cell>Control-266</cell><cell>Total -2062 (india</cell><cell>[n = 1171], Uk</cell><cell>[n = 891])</cell><cell>intervention-1031</cell><cell>Control-1031</cell></row><row><cell>YEAR</cell><cell></cell><cell></cell><cell>2020</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2015</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2015</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2016</cell><cell>2013</cell><cell>2020</cell></row><row><cell>AUThOR</cell><cell></cell><cell></cell><cell>McLeod et al 34</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Block et al 31</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Fukuoka et al 30</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Fischer et al 29</cell><cell>Ramachandran</cell><cell>et al 38</cell><cell>Nanditha et al 32</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_Ud27mub"><s xml:id="_evAvbZV">(Continued)</s></p></div></figDesc><table><row><cell>efficacy by changes in HbA1c levels from baseline to the end of 12-month interventions with Block et al 31 demonstrating sig-nificant reductions in HbA1c (-2.8 mmol/mol [95% CI -0.27, -0.24], P = .002) from a DPP mediated through individually tailored websites and interactive emails. Katula et al's 33 study demonstrated a shift in HbA1c levels from the prediabetes to the normal range (-0.23% [95% CI -0.26, -0.20]) due to an change in weight or BMI. Fukuoka et al's 30 mixed intervention The primary outcome of the 2 studies 29,30 was a percentage difference between study arms. individual and peer support coaching intervention showed no mediated DPP, while McLeod et al's 34 mobile and web-based internet-accessible device (mobile, computer, smartwatch)</cell><cell>with in-person DPP sessions, supplementary interactive mobile app and pedometer use proved effective in weight loss (6.8% [95% CI,4.6,9.1]) while Fischer et al 29 proved the efficacy of text-message enhancement of DPPs in Spanish populations with a comparable portion of the study population losing 3% baseline weight (47.1% [95% CI 33.4-60.8]) compared to English speakers (20.6% [95% CI 7/0-34.2]).</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2 .</head><label>2</label><figDesc><div><p xml:id="_mCWKnGJ"><s xml:id="_wNNMec4">The primary outcomes of the reviewed randomized controlled trials.</s></p></div></figDesc><table><row><cell>AUThOR</cell><cell>DURATiON</cell><cell>MEASUREMENT</cell><cell>iNTERVENTiON (MEAN</cell><cell>CONTROL (MEAN</cell><cell>RiSk RATiO (95% Ci)</cell></row><row><cell></cell><cell></cell><cell>OF ThE PRiMARY</cell><cell>ChANgES ± SD)</cell><cell>ChANgES ± SD)</cell><cell>P-VALUE</cell></row><row><cell></cell><cell></cell><cell>OUTCOME</cell><cell></cell><cell></cell><cell></cell></row><row><cell>McLeod et al 34</cell><cell>12 mo</cell><cell>hbA1c and weight (kg)</cell><cell>hbA1c: 0.0 mmol/mol</cell><cell>hbA1c: 0.0 mmol/mol</cell><cell>hbA1c: 95% Ci -0.9,</cell></row><row><cell></cell><cell></cell><cell>change from baseline</cell><cell>Weight: -1.1 kg</cell><cell>Weight: -0.7 kg</cell><cell>0.9; P = .990,</cell></row><row><cell></cell><cell></cell><cell>to 12-month follow-up</cell><cell></cell><cell></cell><cell>(intervention vs</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>control)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Weight: 95% Ci -1.8,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>-0.5; P = .396</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(intervention vs</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>control)</cell></row><row><cell>Block et al 31</cell><cell>12 mo</cell><cell>hbA1c and fasting</cell><cell>hbA1c: -2.81 mmol/mol,</cell><cell>hbA1c: -1.93 mmol/</cell><cell>hbA1c: 95% Ci</cell></row><row><cell></cell><cell></cell><cell>glucose at 6 mo</cell><cell>-0.26%</cell><cell>mol, -0.18%</cell><cell>-0.27, 0.24; P = .002</cell></row><row><cell></cell><cell></cell><cell></cell><cell>FBg: -0.41 mmol/L</cell><cell>FBg: -0.21 mmol/L</cell><cell>FBg: 95% Ci -0.44,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>-0.12; P &lt; .001</cell></row><row><cell>katula et al 33</cell><cell>12 mo</cell><cell>Change in hbA1c from</cell><cell>-0.23% (95% Ci = -0.26,</cell><cell>-0.16% (95%</cell><cell>P = .001</cell></row><row><cell></cell><cell></cell><cell>baseline to 12 mo</cell><cell>-0.20)</cell><cell>Ci = -0.19, -0.12)</cell><cell></cell></row><row><cell>Fukuoka et al 30</cell><cell>5 mo</cell><cell>% Change in weight</cell><cell>Change in weight of</cell><cell>Change in weight of</cell><cell>Weight change:</cell></row><row><cell></cell><cell></cell><cell>and BMi from baseline</cell><cell>-6.2 ± 5.9 kg</cell><cell>0.3 ± 2.7 kg</cell><cell>95% Ci 4.6, 9.1;</cell></row><row><cell></cell><cell></cell><cell>to 5-month follow-up</cell><cell>Change in weight (%)</cell><cell>Change in weight (%)</cell><cell>P &lt; .001</cell></row><row><cell></cell><cell></cell><cell></cell><cell>-6.8 ± 5.4</cell><cell>0.3 ± 3.0</cell><cell>BMi: P &lt; .001</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Change in BMi</cell><cell>Change in BMi of</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>of-2.2 ± 2.2 kg/m 2</cell><cell>0.1 ± 1.0 kg/m 2</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Change in BMi (%)</cell><cell>Change in BMi (%)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>-6.6 ± 5.7</cell><cell>0.3 ± 3.0</cell><cell></cell></row><row><cell>Fischer et al 29</cell><cell>12 mo</cell><cell>Change in mean</cell><cell>-2.6 lb (95% Ci -5.5 -0.2)</cell><cell>-0.6 lb (95% Ci -2.7</cell><cell>P = .05</cell></row><row><cell></cell><cell></cell><cell>weight (lb)</cell><cell></cell><cell>to 1.6)</cell><cell></cell></row><row><cell>Ramachandran</cell><cell>24 mo</cell><cell>incidence of T2DM</cell><cell>50 (18%)</cell><cell>73 (27%)</cell><cell>hazard ratio 0•64,</cell></row><row><cell>et al 38</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>95% Ci 0.45, 0.92;</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>P = 0•015</cell></row><row><cell>Nanditha et al 32</cell><cell>24 mo</cell><cell>incidence of T2DM:</cell><cell>234 (22.7%)</cell><cell>216 (21.0%)</cell><cell>0.89; 95% Ci 0.74,</cell></row><row><cell></cell><cell></cell><cell>hbA1c ⩾ 6.5%</cell><cell></cell><cell></cell><cell>1.07; P = .22</cell></row><row><cell></cell><cell></cell><cell>(48 mmol/mol)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Wong et al 36</cell><cell>36 mo</cell><cell>incidence rate of DM</cell><cell>12 mo: 3/54 (5.56%)</cell><cell>12 mo: 8/50 (16%)</cell><cell>12 mo: RR: 0.35,</cell></row><row><cell></cell><cell></cell><cell>over 12-and 24-mo</cell><cell>24 mo: 6/54 (11.11%)</cell><cell>24 mo: 9/50 (18%)</cell><cell>95% Ci 0.10, 1.24</cell></row><row><cell></cell><cell></cell><cell>period</cell><cell></cell><cell></cell><cell>24 mo: RR: 0.62,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>95% Ci 0.24, 1.61</cell></row><row><cell>Fottrell et al 37</cell><cell>36 mo</cell><cell>combined prevalence</cell><cell>intermediate</cell><cell>intermediate</cell><cell>0.99; 95% Ci 0.70,</cell></row><row><cell></cell><cell></cell><cell>of T2DM and</cell><cell>hyperglycemic: 315</cell><cell>hyperglycemic: 337</cell><cell>1.39; P = .941</cell></row><row><cell></cell><cell></cell><cell>intermediate</cell><cell>(43.9%)</cell><cell>(47.3%)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>hyperglycemia at the</cell><cell>Diabetes: 122 (17%)</cell><cell>Diabetes: 126 (17.7%)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>end of the intervention</cell><cell>Combined: 437 (60.9%)</cell><cell>Combined: 463 (65%)</cell><cell></cell></row><row><cell cols="6">Abbreviations: BMi, body mass index; DPP, diabetes prevention program; FBg, fasting blood glucose; hbA1c, hemoglobin A1c; RCT, randomized controlled trial; T2DM,</cell></row><row><cell cols="2">type 2 diabetes mellitus; RR, risk ratio.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note xml:id="_3KsnCf8"><p>comparison to standard care (-18% [hazard ratio 0.64, 95% CI 0.45, 0.92; P = 015]; -11.11% [95% CI, 0.24, 1.61, P = .021]). Fortrell et al's<ref type="bibr" target="#b36">37</ref> </p><p>voice-messaging intervention and Nanditha et al's<ref type="bibr" target="#b31">32</ref> </p><p><s xml:id="_EcCQGRH">contrastingly, showed no evidence of effect between intervention and control cohorts.</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_xtHzJfr">Acknowledgements</head><p xml:id="_Qma6xep"><s xml:id="_Ta87cdV">We thank <rs type="person">Dr John Eme</rs> for his help during the review of the manuscript.</s></p></div>
			</div>

			<div type="funding">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_ND3Q7Nc"><p xml:id="_MRH3EAs"><s xml:id="_uqrA7ry">for the research, authorship, and/</s></p></div>
			</div>


			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bV2HDfa">Availability of data and materials</head><p xml:id="_vQ6QBzm"><s xml:id="_bat5qnJ">Data for this study has been presented in the text.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ANQRaeP">Declarations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_rU6eJjD">Ethics approval and consent to participate</head><p xml:id="_vvuZpFT"><s xml:id="_KmqQeem">Ethics was not required, however, the study protocol was registered with the International Prospective Register of Systematic Reviews PROSPERO (#: CRD42022344100).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_e79S3aQ">Consent for publication</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vtNZUsb">Not applicable</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_VXp6ZGb">Author contribution(s)</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<author>
			<persName><forename type="first">A</forename><surname>Sapra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bhandari</surname></persName>
		</author>
		<title level="m" xml:id="_eTHC3YH">Diabetes Mellitus</title>
		<imprint>
			<publisher>StatPearls Publishing LLC</publisher>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sapra A, Bhandari P. Diabetes Mellitus. StatPearls Publishing LLC; 2022.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_w78rfFS">IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045</title>
		<author>
			<persName><forename type="first">H</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Saeedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Karuranga</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2023.110945</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DpVND8k">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page">109119</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_zMYSjTn">Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wVcGvq6">Int J Med Sci</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1185" to="1200" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014;11: 1185-1200.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_mMCzYzH">Use of mobile health technology in the prevention and management of diabetes mellitus</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yingling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Powell-Wiley</forename><surname>Tm</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11886-016-0796-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_v8kcngg">Curr Cardiol Rep</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="130" to="211" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hartz J, Yingling L, Powell-Wiley TM. Use of mobile health technology in the prevention and management of diabetes mellitus. Curr Cardiol Rep. 2016;18: 130-211.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_E46Rt9K">The Finnish diabetes prevention study (DPS) lifestyle intervention and 3-year results on diet and physical activity</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lindström</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Louheranta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mannelin</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.26.12.3230</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EjY5k7U">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="3230" to="3236" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lindström J, Louheranta A, Mannelin M, et al. The Finnish diabetes prevention study (DPS) lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26:3230-3236.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_2UdeqBs">The Diabetes Prevention Program (DPP) description of lifestyle intervention</title>
		<author>
			<orgName type="collaboration">Diabetes Prevention Program Research Group</orgName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_farUkNZ">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="2165" to="2171" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Diabetes Prevention Program Research Group. The Diabetes Prevention Pro- gram (DPP) description of lifestyle intervention. Diabetes Care. 2002;25: 2165-2171.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_Ybs4rqd">Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study</title>
		<author>
			<persName><forename type="first">X-R</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-H</forename><surname>Hu</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.20.4.537</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2YdBYax">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="537" to="544" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pan X-R, Li GW, Hu Y-H, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and dia- betes study. Diabetes Care. 1997;20:537-544.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_Ct8FSwE">The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ramachandran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Snehalatha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mary</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YmaZNQy">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="289" to="297" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ramachandran A, Snehalatha C, Mary S, et al. The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 dia- betes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabe- tologia. 2006;49:289-297.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_8j2Szzt">Global aetiology and epidemiology of type 2 diabetes mellitus and its complications</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Ley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UQQfPsz">Nat Rev Endocrinol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="88" to="98" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88-98.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_nTCNdF6">Evaluation of a digital diabetes prevention program adapted for the medicaid population: study design and methods for a non-randomized, controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Castro</forename><surname>Sweet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.conctc.2018.05.007</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vr4tAwS">Contemp Clin Trials Commun</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="161" to="168" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kim SE, Castro Sweet CM, Gibson E, et al. Evaluation of a digital diabetes pre- vention program adapted for the medicaid population: study design and methods for a non-randomized, controlled trial. Contemp Clin Trials Commun. 2018;10:161-168.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_ESkhWKb">The role of patient education in the prevention and management of type 2 diabetes: an overview</title>
		<author>
			<persName><forename type="first">A</forename><surname>Coppola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sasso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bagnasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Giustina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gazzaruso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bRatMs3">Endocrine</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="18" to="27" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Coppola A, Sasso L, Bagnasco A, Giustina A, Gazzaruso C. The role of patient education in the prevention and management of type 2 diabetes: an overview. Endocrine. 2016;53:18-27.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_jNg8cK5">Public health approaches to type 2 diabetes prevention: the US national diabetes prevention program and beyond</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Gruss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nhim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gregg</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11892-019-1200-z</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NEuf9fA">Curr Diab Rep</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gruss SM, Nhim K, Gregg E, et al. Public health approaches to type 2 diabetes prevention: the US national diabetes prevention program and beyond. Curr Diab Rep. 2019;19:1-11.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_9cgJfGK">Evolving trends in the epidemiology, risk factors, and prevention of type 2 diabetes: a review</title>
		<author>
			<persName><forename type="first">A</forename><surname>Weisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Fazli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Johns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Booth</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cjca.2018.03.002</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bwWdgQh">Can J Cardiol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="552" to="564" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Weisman A, Fazli GS, Johns A, Booth GL. Evolving trends in the epidemiology, risk factors, and prevention of type 2 diabetes: a review. Can J Cardiol. 2018;34:552-564.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_YJTGUCQ">Ethical issues in digital health</title>
		<author>
			<persName><forename type="first">Akl</forename><surname>Jumelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ispas</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-3-319-09798-5_4</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_DhU35ma">Requirements Engineering for Digital Health</title>
		<editor>
			<persName><forename type="first">S</forename><surname>Fricker</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">C</forename><surname>Thümmler</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">A</forename><surname>Gavras</surname></persName>
		</editor>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="2014">2014</date>
			<biblScope unit="page" from="75" to="93" />
		</imprint>
	</monogr>
	<note type="raw_reference">Jumelle AKL, Ispas I. Ethical issues in digital health. In: Fricker S, Thümmler C, Gavras A, eds. Requirements Engineering for Digital Health. Springer; 2014:75-93.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main" xml:id="_vAeqwvt">The Use and Impact of Digital Technology on Population Health and Health Equity Gains: A Sponsored E-supplement</title>
		<author>
			<persName><forename type="first">P</forename><surname>Freeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anthony</forename><surname>Robbins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-E</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
			<publisher>Springer</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Freeman P, Anthony Robbins C-E. The Use and Impact of Digital Technology on Population Health and Health Equity Gains: A Sponsored E-supplement. Springer; 2016.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main" xml:id="_FnbKun8">How digital tools can help to cross borders in international collaborations</title>
		<author>
			<persName><forename type="first">V</forename><surname>Seyfert-Margolis</surname></persName>
		</author>
		<author>
			<persName><surname>Sp</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2018-eular.7684</idno>
		<imprint>
			<date type="published" when="2018">0020. 2018</date>
			<publisher>BMJ Publishing Group Ltd</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Seyfert-Margolis V. SP0020 How digital tools can help to cross borders in interna- tional collaborations. BMJ Publishing Group Ltd; 2018.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_epyftKt">The transformation of health care for patients: information and communication technology, digiceuticals, and digitally enabled care</title>
		<author>
			<persName><forename type="first">E</forename><surname>Downes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Horigan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Teixeira</surname></persName>
		</author>
		<idno type="DOI">10.1097/jxx.0000000000000109</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_G8746Zd">J Am Assoc Nurse Pract</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="156" to="161" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Downes E, Horigan A, Teixeira P. The transformation of health care for patients: information and communication technology, digiceuticals, and digitally enabled care. J Am Assoc Nurse Pract. 2019;31:156-161.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_yCADPBx">e-Health innovation: time for engagement with the cardiology community</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Cowie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Chronaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vardas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TrKBJCH">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1864" to="1868" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cowie MR, Chronaki CE, Vardas P. e-Health innovation: time for engagement with the cardiology community. Eur Heart J. 2013;34:1864-1868.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_SE8YWAP">Back to the future: Emerging technology, social, and cultural trends affecting consumer informatics</title>
		<author>
			<persName><forename type="first">M</forename><surname>Edmunds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Holve</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-3-319-96906-0_20</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kN2YyyX">Consumer Informatics and Digital Health: Solutions for Health and Health Care</title>
		<editor>
			<persName><forename type="first">M</forename><surname>Edmunds</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">C</forename><surname>Hass</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">E</forename><surname>Holve</surname></persName>
		</editor>
		<imprint>
			<biblScope unit="page" from="377" to="398" />
			<date type="published" when="2019">2019</date>
			<publisher>Springer</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Edmunds M, Hass C, Holve E. Back to the future: Emerging technology, social, and cultural trends affecting consumer informatics. In: Edmunds M, Hass C, Holve E, eds. Consumer Informatics and Digital Health: Solutions for Health and Health Care. Springer; 2019:377-398.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_yD9Tu93">The global agenda for the prevention of type 2 diabetes</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Herman</surname></persName>
		</author>
		<idno type="DOI">10.1093/nutrit/nuw034</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2ZyqFvP">Nutr Rev</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="13" to="18" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Herman WH. The global agenda for the prevention of type 2 diabetes. Nutr Rev. 2017;75:13-18.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_gnqpM7B">Improving diabetes care with technology and information management</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Muegge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Tobin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PmY2c34">Mo Med</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="367" to="371" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Muegge BD, Tobin GS. Improving diabetes care with technology and informa- tion management. Mo Med. 2016;113:367-371.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_AS7vDcv">Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">K</forename><surname>Pal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Eastwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Michie</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd008776</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_njpVdNY">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">2013</biblScope>
			<biblScope unit="page">8776</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pal K, Eastwood SV, Michie S, et al. Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;2013:CD008776.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main" xml:id="_Z6GPfT3">Cochrane Handbook for Systematic Reviews of Interventions</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chandler</surname></persName>
		</author>
		<idno type="DOI">10.1002/9781119536604</idno>
		<imprint>
			<date type="published" when="2019">2019</date>
			<publisher>John Wiley &amp; Sons</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Higgins JP, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley &amp; Sons; 2019.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_JrWsRQN">PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Methley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chew-Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mcnally</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cheraghi-Sohi</surname></persName>
		</author>
		<author>
			<persName><surname>Pico</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12913-014-0579-0</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ch7K728">BMC Health Serv Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">579</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14:579.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_j8SGJs4">The Cochrane collaboration&apos;s tool for assessing risk of bias in randomised trials</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Gøtzsche</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.d5928</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qAKyy2N">BMJ</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page">5928</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration&apos;s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_e2uCzAt">Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Mcguinness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jpt</forename><surname>Higgins</surname></persName>
		</author>
		<idno type="DOI">10.1002/jrsm.1411</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KvMv58b">Res Synth Methods</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="55" to="61" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R pack- age and shiny web app for visualizing risk-of-bias assessments. Res Synth Meth- ods. 2021;12:55-61.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_mCGW4RJ">GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Vist</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.39489.470347.ad</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YtfHw3C">BMJ</title>
		<imprint>
			<biblScope unit="volume">336</biblScope>
			<biblScope unit="page" from="924" to="926" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336: 924-926.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_f4cZMta">The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Page</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Mckenzie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Bossuyt</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.n71</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JsYNqpw">BMJ</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page">71</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_cNeGue5">Text message support for weight loss in patients with prediabetes: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">P</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Pereira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_t73XG6f">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1364" to="1370" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fischer HH, Fischer IP, Pereira RI, et al. Text message support for weight loss in patients with prediabetes: a randomized clinical trial. Diabetes Care. 2016;39:1364-1370.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_kUCYD8E">A novel diabetes prevention intervention using a mobile app: a randomized controlled trial with overweight adults at risk</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Fukuoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Gay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Joiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vittinghoff</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amepre.2015.01.003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KRkx3Z9">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="223" to="237" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fukuoka Y, Gay CL, Joiner KL, Vittinghoff E. A novel diabetes prevention intervention using a mobile app: a randomized controlled trial with overweight adults at risk. Am J Prev Med. 2015;49:223-237.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_Ur26UKC">Diabetes prevention and weight loss with a fully automated behavioral intervention by email, web, and mobile phone: a randomized controlled trial among persons with prediabetes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Block</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Azar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Romanelli</surname></persName>
		</author>
		<idno type="DOI">10.2196/jmir.4897</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MFc57dg">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">e240</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Block G, Azar KM, Romanelli RJ, et al. Diabetes prevention and weight loss with a fully automated behavioral intervention by email, web, and mobile phone: a randomized controlled trial among persons with prediabetes. J Med Internet Res. 2015;17:e240.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_qSnYf97">A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomised controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nanditha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Thomson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Susairaj</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00125-019-05061-y</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gPFpmUZ">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="486" to="496" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nanditha A, Thomson H, Susairaj P, et al. A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomised controlled trial. Diabetologia. 2020;63:486-496.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_DUeywzE">Effects of a digital diabetes prevention program: an RCT</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Katula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">V</forename><surname>Dressler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Kittel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9BsDpwr">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="567" to="577" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Katula JA, Dressler EV, Kittel CA, et al. Effects of a digital diabetes prevention program: an RCT. Am J Prev Med. 2022;62:567-577.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_y2PSe2k">Impact of a comprehensive digital health programme on HbA(1c) and weight after 12 months for people with diabetes and prediabetes: a randomised controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mcleod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stanley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Signal</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00125-020-05261-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZAtGhE5">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="2559" to="2570" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McLeod M, Stanley J, Signal V, et al. Impact of a comprehensive digital health programme on HbA(1c) and weight after 12 months for people with diabetes and prediabetes: a randomised controlled trial. Diabetologia. 2020;63:2559-2570.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_AQHsyW4">Text4Diet: a randomized controlled study using text messaging for weight loss behaviors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Shapiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Koro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Doran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pjtJFCB">Prev Med</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="412" to="417" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shapiro JR, Koro T, Doran N, et al. Text4Diet: a randomized controlled study using text messaging for weight loss behaviors. Prev Med. 2012; 55:412-417.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_VsApxaX">A short message service (SMS) intervention to prevent diabetes in Chinese professional drivers with pre-diabetes: a pilot single-blinded randomized controlled trial</title>
		<author>
			<persName><forename type="first">Ckh</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Csc</forename><surname>Fung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Siu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_H7S9rp6">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="158" to="166" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wong CKH, Fung CSC, Siu SC, et al. A short message service (SMS) interven- tion to prevent diabetes in Chinese professional drivers with pre-diabetes: a pilot single-blinded randomized controlled trial. Diabetes Res Clin Pract. 2013;102:158-166.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_XerUgTt">Community groups or mobile phone messaging to prevent and control type 2 diabetes and intermediate hyperglycaemia in Bangladesh (DMagic): a cluster-randomised controlled trial</title>
		<author>
			<persName><forename type="first">E</forename><surname>Fottrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Morrison</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2213-8587(19)30001-4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RHCWEMv">Lancet Diabetes Endocrinol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="200" to="212" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fottrell E, Ahmed N, Morrison J, et al. Community groups or mobile phone messaging to prevent and control type 2 diabetes and intermediate hyperglycae- mia in Bangladesh (DMagic): a cluster-randomised controlled trial. Lancet Dia- betes Endocrinol. 2019;7:200-212.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_DHVycPY">Effectiveness of mobile phone messaging in prevention of type 2 diabetes by lifestyle modification in men in India: a prospective, parallel-group, randomised controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ramachandran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Snehalatha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ram</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GsHbxQf">Lancet Diabetes Endocrinol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="191" to="198" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ramachandran A, Snehalatha C, Ram J, et al. Effectiveness of mobile phone messaging in prevention of type 2 diabetes by lifestyle modification in men in India: a prospective, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2013;1:191-198.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_WnsGeZE">A review of technology-assisted interventions for diabetes prevention</title>
		<author>
			<persName><forename type="first">S</forename><surname>Grock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Ku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Moin</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11892-017-0948-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PxBTt9m">Curr Diab Rep</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="107" to="112" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Grock S, Ku JH, Kim J, Moin T. A review of technology-assisted interventions for diabetes prevention. Curr Diab Rep. 2017;17:107-112.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_yPyNKfA">Prevention of type 2 diabetes-success story that is waiting for next steps</title>
		<author>
			<persName><forename type="first">M</forename><surname>Uusitupa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lindström</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tuomilehto</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41430-018-0223-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EE5wYGp">Eur J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1260" to="1266" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Uusitupa M, Lindström J, Tuomilehto J. Prevention of type 2 diabetes-success story that is waiting for next steps. Eur J Clin Nutr. 2018;72:1260-1266.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_Q9p3m6A">Barriers to self-management of diabetes</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Ahola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Groop</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8URXxFC">Diabetic Med</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="413" to="420" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ahola AJ, Groop PH. Barriers to self-management of diabetes. Diabetic Med. 2013;30:413-420.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_j8wD8A3">Tailored, interactive text messages for enhancing weight loss among African American adults: the TRIMM randomized controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Mahmooth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dedhia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KuBwe9c">Am J Med</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="896" to="904" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lin M, Mahmooth Z, Dedhia N, et al. Tailored, interactive text messages for enhancing weight loss among African American adults: the TRIMM random- ized controlled trial. Am J Med. 2015;128:896-904.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_UkCeUzH">A meta-analysis of overall effects of weight loss interventions delivered via mobile phones and effect size differences according to delivery mode, personal contact, and intervention intensity and duration</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schippers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Adam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Smolenski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>De Wit</surname></persName>
		</author>
		<idno type="DOI">10.1111/obr.12492</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UKQEfWy">Obes Rev</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="450" to="459" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schippers M, Adam PC, Smolenski DJ, Wong HT, de Wit JB. A meta-analysis of overall effects of weight loss interventions delivered via mobile phones and effect size differences according to delivery mode, personal contact, and inter- vention intensity and duration. Obes Rev. 2017;18:450-459.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
